ReviewCancers2023
Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 32 citations in OpenAlex.
- EGR1 regulates IGF-1-stimulated pancreatic cancer cell invasion by increasing IL-11 expression.Oncology letters · 2026Article
- Gut Microbiota and Brain Aging: Identifying Keystone Biomarkers for Cognitive Health.Biomedicines · 2026Review
- Human biomarker navigator.iMeta · 2026Review
- Article
- Evidence for a Potential Context-Dependent Dual Role of Eb Peptide of IGF-1Eb in Cancer Cell Survival and Adaptation to UV Stress.International journal of molecular sciences · 2026Article
- Beyond the membrane: Internalization and compartmentalization of insulin‑like growth factor 1 receptor signaling in cancer pathogenesis and treatment (Review).International journal of oncology · 2026Review
- Article
- In-silico and In-vitro Gene Expression Analysis on Docetaxel and Methotrexate-induced Cytotoxicity in Oral Cancer Cell Line.Cell biochemistry and biophysics · 2026Article
- Mechanistic insights and clinical implications of RNA-binding proteins in prostate cancer.Discover oncology · 2026Review
- The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and treatment strategies.International journal of surgery (London, England) · 2026Article
- A U-shaped association between blood selenium levels and prostate cancer: findings of a case-control study among Nigerian men.Scientific reports · 2025Article
- DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.Nucleic acids research · 2025Article
- Quantitative Real-Time RT-PCR Verifying Gene Expression Profile of Cavitations Within Human Jaw Bone.Biomedicines · 2025Article
- From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections.Reviews in endocrine & metabolic disorders · 2025Review
- DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.bioRxiv : the preprint server for biology · 2025Article
- Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.Signal transduction and targeted therapy · 2025Review
- Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts.Frontiers in pharmacology · 2025Article
- Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1.Journal of clinical medicine · 2024Article
- Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.British journal of cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa) is a highly heterogeneous disease driven by gene alterations and microenvironmental influences. Not only enhanced serum IGF-1 but also the activation of IGF-1R and its downstream signaling components has been increasingly recognized to have a vital driving role in the development of PCa. A better understanding of IGF-1/IGF-1R activity and regulation has therefore emerged as an important subject of PCa research. IGF-1/IGF-1R signaling affects diverse biological processes in cancer cells, including promoting survival and renewal, inducing migration and spread, and promoting resistance to radiation and castration. Consequently, inhibitory reagents targeting IGF-1/IGF-1R have been developed to limit cancer development. Multiple agents targeting IGF-1/IGF-1R signaling have shown effects against tumor growth in tumor xenograft models, but further verification of their effectiveness in PCa patients in clinical trials is still needed. Combining androgen deprivation therapy or cytotoxic chemotherapeutics with IGF-1R antagonists based on reliable predictive biomarkers and developing and applying novel agents may provide more desirable outcomes. This review will summarize the contribution of IGF-1 signaling to the development of PCa and highlight the relevance of this signaling axis in potential strategies for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.